U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06794554) titled 'Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults with Limited Treatment Options' on Nov. 26, 2024.
Brief Summary: The goal of this clinical trial is to to evaluate the drug rezafungin in the treatment of Chronic Pulmonary Aspergillosis (CPA) in male and female patients aged 18 years and over with limited treatment options.
The study aims to answer whether 6 months of rezafungin treatment is effective and safe in patients with chronic pulmonary aspergillosis with limited treatment options according to clinical and radiological response as measured by the St George's Respiratory Questionnaire, weight, and C...